GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody and forms the backbone of GSK's immuno-oncology research and development program. The drug is currently being studied in various ...

IDRX-42 adds to GSK’s existing gastrointestinal cancer programmes, which include ongoing clinical trials with checkpoint inhibitor Jemperli (dostarlimab) and the B7-H3-targeted antibody-drug ...

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...